Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors

ACS Medicinal Chemistry Letters

Volumn 7, Issue 6, 2016, Pages 629-634

  Zhao, Bin ^a   Li, Yixuan ^a   Xu, Pan ^a   Dai, Yang ^a   Luo, Cheng ^a   Sun, Yiming ^a   Ai, Jing ^a   Geng, Meiyu ^a   Duan, Wenhu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cancer; FGFR; inhibitor; pyrazolo 3,4 b pyridine

Indexed keywords

AZD 4547; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLO[3,4 B]PYRIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; IC50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH INHIBITION RATE; TUMOR XENOGRAFT;

EID: 84974530317     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00066     Document Type: Article

References (17)

1. Belov, A. A.; Mohammadi, M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology Cold Spring Harbor Perspect. Biol. 2013, 5, a015958/1-a015958/24 10.1101/cshperspect.a015958
2. Laestander, C.; Engström, W. Role of fibroblast growth factors in elicitation of cell responses Cell Proliferation 2014, 47, 3-11 10.1111/cpr.12084
3. Carter, E. P.; Fearon, A. E.; Grose, R. P. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction Trends Cell Biol. 2015, 25, 221-233 10.1016/j.tcb.2014.11.003
4. Turner, N.; Grose, R. Fibroblast growth factor signalling: from development to cancer Nat. Rev. Cancer 2010, 10, 116-129 10.1038/nrc2780
5. Brooks, A. N.; Kilgour, E.; Smith, P. D. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer Clin. Cancer Res. 2012, 18, 1855-1862 10.1158/1078-0432.CCR-11-0699
6. Knights, V.; Cook, S. J. De-regulated FGF receptors as therapeutic targets in cancer Pharmacol. Ther. 2010, 125, 105-117 10.1016/j.pharmthera.2009.10.001
7. Touat, M.; Ileana, E.; Postel-Vinay, S.; André, F.; Soria, J. C. Targeting FGFR signaling in cancer Clin. Cancer Res. 2015, 21, 2684-2694 10.1158/1078-0432.CCR-14-2329
8. Greulich, H.; Pollock, P. M. Targeting mutant fibroblast growth factor receptors in cancer Trends Mol. Med. 2011, 17, 283-292 10.1016/j.molmed.2011.01.012
9. Ho, H. K.; Yeo, A. H.; Kang, T. S.; Chua, B. T. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations Drug Discovery Today 2014, 19, 51-62 10.1016/j.drudis.2013.07.021
10. Ronca, R.; Giacomini, A.; Rusnati, M.; Presta, M. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis Expert Opin. Ther. Targets 2015, 19, 1361-1377 10.1517/14728222.2015.1062475
11. Lemieux, S.; Hadden, M. K. Targeting the fibroblast growth factor receptors for the treatment of cancer Anti-Cancer Agents Med. Chem. 2013, 13, 748-761 10.2174/18715206113139990080
12. Izzedine, H.; Ederhy, S.; Goldwasser, F.; Soria, J. C.; Milano, G.; Cohen, A.; Khayat, D.; Spano, J. P. Management of hypertension in angiogenesis inhibitor-treated patients Ann. Oncol. 2009, 20, 807-815 10.1093/annonc/mdn713
13. Ricciardi, S.; Tomao, S.; de Marinis, F. Toxicity of targeted therapy in non-small-cell lung cancer management Clin. Lung Cancer 2009, 10, 28-35 10.3816/CLC.2009.n.004
14. Guagnano, V.; Furet, P.; Spanka, C.; Bordas, V.; Le Douget, M.; Stamm, C.; Brueggen, J.; Jensen, M. R.; Schnell, C.; Schmid, H.; Wartmann, M.; Berghausen, J.; Drueckes, P.; Zimmerlin, A.; Bussiere, D.; Murray, J.; Graus Porta, D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase J. Med. Chem. 2011, 54, 7066-7083 10.1021/jm2006222
15. Gavine, P. R.; Mooney, L.; Kilgour, E.; Thomas, A. P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M. J.; Brooks, A. N.; Klinowska, T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family Cancer Res. 2012, 72, 2045-2056 10.1158/0008-5472.CAN-11-3034
16. Nakanishi, Y.; Akiyama, N.; Tsukaguchi, T.; Fujii, T.; Sakata, K.; Sase, H.; Isobe, T.; Morikami, K.; Shindoh, H.; Mio, T.; Ebiike, H.; Taka, N.; Aoki, Y.; Ishii, N. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor Mol. Cancer Ther. 2014, 13, 2547-2558 10.1158/1535-7163.MCT-14-0248
17. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain EMBO J. 1998, 17, 5896-5904 10.1093/emboj/17.20.5896